Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1632 1637 1638 1646
This examiner grants 50% of resolved cases
Lexus Marc Tatge is an examiner in Tech Center 1600 and Art Unit 1600. With 2 resolved cases, the current allowance rate_pct is 50.0. The data also shows an interview lift_pct of 100.0, indicating that for these cases, an interview was a factor in reaching an allowance.
The median_days_to_allowance for this examiner is 1245. These figures provide an initial look at the prosecution environment for this profile. Practitioners should note the 50.0 allowance rate_pct and the 100.0 interview lift_pct when planning their approach in this art unit. The 1245-day timeline serves as a baseline for pendency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18700487 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | Non-Final OA | Intellia Therapeutics, Inc. |
| 17618313 | ANTISENSE RNA EDITING OLIGONUCLEOTIDES COMPRISING CYTIDINE ANALOGS | Non-Final OA | The Regents of the University of California |
| 18271684 | REPROGRAMMABLE TNPB POLYPEPTIDES AND USE THEREOF | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18688282 | LIPOPHILIC OLIGONUCLEOTIDE CONJUGATES | Non-Final OA | Vanderbilt University |
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18057298 | Methods Of Treating Headaches And Migraines With Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) Inhibitors | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18274327 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18251384 | ENHANCEMENT OF PREDICTABLE AND TEMPLATE-FREE GENE EDITING BY THE ASSOCIATION OF CAS WITH DNA POLYMERASE | Non-Final OA | New York University |
| 18366403 | HUMAN ORAL MUCOSA STEM CELL SECRETOME | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18263085 | COMPOSITIONS AND METHODS FOR TREATMENT OF NIEMANN PICK TYPE A DISEASE | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18659711 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLON CANCER INCLUDING EXTRACELLULAR VESICLES LOADED WITH MACC1 INHIBITOR AS ACTIVE INGREDIENT | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18554636 | TKTL1 INHIBITORS FOR ANTIVIRAL THERAPY | Non-Final OA | Tavargenix GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy